Back to search

Article

Little genomic support for cyclophilin A-matrix metalloproteinase-9 pathway as a therapeutic target for cognitive impairment in <i>APOE4</i> carriers

2021-04-22

Abstract excerpt

Therapeutic targets for halting the progression of Alzheimers disease pathology are lacking. Recent evidence suggests that APOE4, but not APOE3, activates the cyclophilin A matrix metalloproteinase-9 (CypA MMP9) pathway in the cerebrospinal fluid, leading to an accelerated breakdown of the blood brain barrier (BBB) and thereby causing neuronal and synaptic dysfunction. Furthermore, blockade of the CypA MMP9 pathwa...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
6e2c99fb-b850-591c-878e-bed645f5ee2e
DOI
10.1101/2021.04.22.21255729
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Little genomic support for cyclophilin A-matrix metalloproteinase-9 pathway as a therapeutic target for cognitive impairment in <i>APOE4</i> carriersDOI 10.1101/2021.04.22.21255729
Select a neighboring publication to make it the new centre.